Brief: Pharmather Holdings Submits Fast Track Application To FDA For Ketarx For Treatment Of Parkinson's Disease
02/05/2023 12:33
May 2 (Reuters) - Pharmather Holdings Ltd PHRM.CD :
* PHARMATHER HOLDINGS SUBMITS FAST TRACK APPLICATION TO FDA
FOR
KETARX™ (KETAMINE) FOR THE TREATMENT OF PARKINSON’S DISEASE
Source text for Eikon: ID:nGNXbnNX5n
Further company coverage: PHRM.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharmather Holdings
See all newsBrief: Pharmather Sells Ketamine ANDA, Eyes Over $25M In Milestone And Profit-Sharing Payments
Brief: Pharmather receives US FDA approval goal date for Ketamine
Brief: Pharmather Announces Update On FDA New Drug Application For Ketamine
Brief: PharmTther Announces Post Complete Response Letter Clarification Meeting Request Granted From The FDA For Ketamine Abbreviated New Drug Application
Brief: Pharmather Receives Complete Response Letter From The U.S. Food And Drug Administration For Ketamine Abbreviated New Drug Application